ANI Pharmaceuticals | ANIP - Selling And Administration Expenses

Stock Price
77.77
Daily Change
-0.33 -0.42%
Monthly
-9.06%
Yearly
34.23%
Q1 Forecast
75.36

ANI Pharmaceuticals reported $76.66M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
ANI Pharmaceuticals USD 76.66M 5.11M Sep/2025
Assertio Holdings USD 16.73M 1.66M Sep/2024
Aurora Cannabis CAD 41.79M 3.84M Sep/2025
Canopy Growth CAD 29.53M 999K Sep/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Emergent BioSolutions USD 182.8M 82.3M Jun/2023
Heron Therapeutics USD 23.34M 4.18M Sep/2024
Hikma Pharmaceutical USD 139M 149M Jun/2025
Knight Therapeutics CAD 25.48M 119K Sep/2024
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Novartis USD 3.3B 137M Sep/2025
Omeros USD 11.32M 2.48M Sep/2024
Perrigo USD 245.7M 27.4M Sep/2025
Sun Pharmaceuticals INR 24.89B 637.6M Mar/2025
Teva Pharmaceutical Industries USD 1.12B 147M Dec/2025